Abataceptf

(Orencia®)

Abataceptf

Drug updated on 9/13/2023

Dosage FormInjection (intravenous; 250 mg Injection (subcutaneous; 50 mg/0.4 mL, 87.5 mg/0.7 mL, 125 mg/mL)
Drug ClassT cell co-stimulation modulator
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
  • For the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA).
  • For the treatment of adult patients with active psoriatic arthritis (PsA).
  • For the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor.